Eva Soler Espejo։ Atherogenic Index of Plasma and Residual Risk in Atrial Fibrillation
Eva Soler Espejo, Consultant Hematologist at Virgen de la Arrixaca University Clinical Hospital, shared a post on LinkedIn about a recent article she co-authored with her colleagues, adding:
”Anticoagulation in atrial fibrillation reduces risk — but does not eliminate it completely.
I am very pleased to share our latest publication in the Journal of the American Heart Association (JAHA).
In this prospective real-world study of anticoagulated patients with atrial fibrillation, we investigated whether the Atherogenic Index of Plasma (AIP) could help identify residual cardiovascular and thromboembolic risk.
Higher AIP levels were independently associated with worse clinical outcomes, particularly thromboembolic events and major adverse cardiovascular events (MACE), suggesting that this simple metabolic marker may provide incremental prognostic value beyond conventional risk assessment.
These findings underline the importance of better understanding residual risk in order to move towards more personalised and comprehensive management strategies in patients with AF.”
Title: Atherogenic Index of Plasma and Residual Risk in Anticoagulated Patients With Atrial Fibrillation: The Prospective Murcia Atrial Fibrillation Project III Cohort
Authors: Eva Soler‐Espejo, Yang Chen, José M. Rivera‐Caravaca, María P. Ramos‐Bratos, Francisco Marín, Vanessa Roldán, Gregory Y. H. Lip
Read the Full Article on Journal of the American Heart Association
Stay updated on all scientific advances with Hemostasis Today.
-
Nov 8, 2026, 17:57Dhiren Patel: PLD1-Derived Phospholipids Regulate NAD Kinase and ROS Production in Neutrophils
-
Nov 8, 2026, 17:48Andra T.: What Causes Antiphospholipid Syndrome? – Four Steps, not One Cause
-
Nov 8, 2026, 17:38Nasrin Samadi: Can a Normal Clotting Test Be Misleading?
-
Nov 8, 2026, 17:36Paschalis Evangelidis: The Multifactorial Nature of Cardiovascular Risk in People With Hemophilia
-
Nov 8, 2026, 17:32Evangelos Panagiotopoulos: Apixaban Reduces Stroke and Major Bleeding Risk in Secondary Stroke Prevention
-
Nov 8, 2026, 17:27Danny Gaskin: Applications Open for the BBTS Specialist Certificate in Clinical Transfusion Practice
-
Nov 8, 2026, 16:54James P. Crowley: DOAC Testing Under 50 ng/mL Safely Expedites Urgent Hip Fracture Surgery
-
Nov 8, 2026, 16:21Alessandra Bosch: Women and Girls With Bleeding Disorders and the DACH Registries at HHS 2026
-
Nov 8, 2026, 15:0310 Posts Not to Miss This Week